Retatrutide 40 mg is a pre-filled subcutaneous injection designed to support clinically supervised weight management in adults. This prescription medication functions as a triple agonist, targeting GLP-1, GIP, and glucagon receptors to help regulate appetite, enhance satiety, and support metabolic balance.

Each pen contains 40 mg of solution, intended for once-weekly administration, offering precise dosing and convenience for patients under medical supervision. The formulation is provided as a subcutaneous solution for injection and must be refrigerated at 2°C to 8°C to maintain stability and effectiveness.

Manufactured under strict pharmaceutical-grade standards, Alluvi Retatrutide 40 mg ensures consistent potency, safety, and quality, and should only be used as part of a structured diet and lifestyle program under a healthcare professional’s guidance.

Key Features:

• Pre-filled subcutaneous solution for injection

• Triple agonist targeting GLP-1, GIP, and glucagon receptors

• 40 mg per pen, intended for once-weekly use

• Supports clinically supervised weight loss and appetite control

• Requires refrigeration (2°C–8°C)

• Manufactured to pharmaceutical-grade standards

• Prescription-only, for supervised clinical use